Back to Search
CHAD STRUPP, DMD
DMD
General Practice Dentistry
NPI: 1548836414Individual
Specialties, Licenses & Credentials
General Practice DentistryPrimary
Dentist — General Practice
Code: 1223G0001X
1002542-15(WI)
Research & Publications (20)
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.
PMID 19336740·Haematologica·2009
8-other
Impact on survival of different treatments for myelodysplastic syndromes (MDS).
PMID 19185917·Leuk Res·2009
8-other
Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
PMID 19548919·Eur J Haematol·2009
8-other
Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.
PMID 19528370·J Clin Oncol·2009
8-other
Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome.
PMID 17412418·Leuk Res·2008
4-observational
Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification.
PMID 17268513·Leukemia·2007
8-other
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.
PMID 17687155·J Clin Oncol·2007
4-observational
Chronic myelomonocytic leukemia in the light of the WHO proposals.
PMID 17606449·Haematologica·2007
8-other
A pilot study of bendamustine in elderly patients with high-risk MDS and AML.
PMID 17577779·Leuk Lymphoma·2007
8-other
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
PMID 17145595·Haematologica·2006
4-observational
Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals.
PMID 16398650·Br J Haematol·2006
8-other
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
PMID 16270213·Ann Hematol·2005
3-trial
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
PMID 16193087·Leukemia·2005
8-other
The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.
PMID 16019550·Leuk Lymphoma·2005
8-other
Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
PMID 15978949·Leuk Res·2005
5-case
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
PMID 15891887·Ann Hematol·2005
5-case
Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma.
PMID 15510204·Leukemia·2005
8-other
No increase in age-specific incidence of myelodysplastic syndromes.
PMID 15339672·Haematologica·2004
8-other
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
PMID 15155466·Blood·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 410 E WASHINGTON ST
SLINGER, WI 53086 - Phone
- (262) 644-6951
Quick Facts
- NPI
- 1548836414
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile